Biomarker Testing: Harnessing All Sides of the Tumor Microenvironment

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Antitumor Immunity

Process of Cancer Immunoediting

PD-1/PD-L1 Inhibitor Therapies

Inflamed vs Noninflamed Tumor Phenotype

FDA-Approved PD-L1 IHC Antibodies

PD-L1 IHC Antibody Concordance

Clinical Trial Experience: NSCLC

Recommendations for PD-L1 Testing

Protocol for Processing Samples

Advantages and Disadvantages of ROSE in EBUS-TBNA

The Rise of Laboratory-Developed Tests

Realities of PD-L1 Testing

PD-L1 Testing: Factors to Consider

Clinical Trial Experience: Bladder

PD-L1 Testing in Bladder Cancer

Challenges of PD-L1 Testing

Additional Possible Biomarkers: MSI

Increased Response to Immunotherapy Is Correlated With Mutational Burden

Concluding Remarks

Abbreviations